u/hugo_norgaard

dose for glycaemic control is not the same conversation as dose for weight

Yes — nobody here is your clinician, and the good answers on this board all end with that.

I would not treat a two-kilo range as drift requiring action. That is ordinary weight variation.

I would not treat a two-kilo range as drift requiring action.

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

Have you taken this to whoever manages your diabetes?

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

Appetite change and weight change are different measurements on different timescales. The first is usually noticed first and the second lags it.

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

Chased the last three kilos with a dose increase and got a fortnight of injection-site soreness and no change in the number.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

a COA is a certificate of analysis, the lab document for a batch

the diabetes trials report different endpoints from the obesity ones

Yes — nobody here is your clinician, and the good answers on this board all end with that.

discontinuation rate is a result, not a footnote

SURPASS is the diabetes programme and reports glycaemic endpoints

check who the comparator was before you compare anything

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

Same. A press release is a claim about a result; the publication is the result.

I would not treat a two-kilo range as drift requiring action. That is ordinary weight variation.

What was the discontinuation rate?

Not convinced. Interval stretching changes your exposure profile, not just the total, and the two are not equivalent.

the habits are the part that has to outlive the dose

a single high reading is not a trend

regain after stopping is the expected outcome, not a personal failure

trial populations get support that nobody on this board gets

stretching the interval is not the same as reducing the dose

a few kilos of drift is not a relapse

Same. A press release is a claim about a result; the publication is the result.

variability matters as much as the mean

read the endpoint before you read the headline

Week 4 for me was completely flat and I was convinced something was wrong. It was not. Month two was where everything happened.

Took three weeks to understand titration and about ten seconds once somebody explained it as a tolerance ladder.

Correction: that trial measured regain after withdrawal, not failure of the drug during treatment. Very different claim.

no question is too basic here, that is the entire point of the board

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Research-use-only material is not approved for human use. That is a plain statement of regulatory fact and it belongs in every beginner thread.

a single high reading is not a trend

Left up.

Slight disagreement with this bit only, because a beginner reading it might take it as a plan rather than a description.

What does the wiki page on this say — genuinely asking, not deflecting?

This is the answer. Everything else in the thread is elaboration on it.

None of this is a taper plan.

usp_appendix is right that stretching and reducing are different levers. Worth separating in every one of these threads.